FDA approves Talvey for heavily pre-treated multiple myeloma
Janssen’s bispecific antibody received accelerated approval as a subcutaneous therapy based on Phase II trial data.
11 August 2023
11 August 2023
Janssen’s bispecific antibody received accelerated approval as a subcutaneous therapy based on Phase II trial data.
Amid unceasing demand for its blockbuster drug Wegovy, Novo Nordisk is adding a CB1 blocker to its weight loss drug pipeline.
The FDA requested additional trial data before resubmission for Galera’s avasopasem manganese for treating radiotherapy-induced severe oral mucositis.
Palisade Bio’s lead clinical candidate, tranexamic acid, did not meet its primary endpoint of adhesion reduction post-bowel resection surgery.
The sNDA is based on results from a Phase II open-label, non-comparative, multicentre study.
Babylon, Galera and more are cutting staff, serving as a reminder that failure is easy in the medical world.
The teams will focus on developing a novel HIV therapy that can offer protection against infection from all strains of the virus.
XPOVIO secured its approval for use along with dexamethasone to treat adult patients.
We will be launching our new event Clinical Trials In Rare Diseases Conference 2023 at Princeton Marriott at Forrestal, New Jersey, USA on 13th-14th September! Bringing together clinical operations professionals from across multiple therapeutic areas to discuss common obstacles and solutions and much more. With over 40 solution providers this will be a perfect platform to reconnect with current business partners, meet new vendors and discover which new technologies are being employed to improve your Rare Disease clinical trials.
The COVID-19 pandemic pushed the healthcare industry to rapid digitalization. Increased use of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology is changing how healthcare is delivered and improving patient outcomes. Emerging technologies such as AR and VR are becoming increasingly routine for professional training, surgical assistance, and treatment of psychological and neurological disorders. In the pharma and medical devices industries, AR, VR, and AI are rapidly accelerating drug discovery and manufacturing and generating supply chain efficiencies. New digital opportunities will look to build upon disruptive technologies. However, affordability is a limiting factor to widespread adoption. Per GlobalData estimates, the metaverse market is expected to grow at a CAGR of more than 33% between 2023 and 2030. Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.
Give your business an edge with our leading industry insights.